Cardiff Oncology, Inc. Common Stock vs. Halozyme Therapeutics, Inc.
CRDF
Cardiff Oncology, Inc. Common Stock
$0.96 +0.57%
VS HALOHalozyme Therapeutics, Inc.
$85.76 +2.60%
Cardiff Oncology, Inc. Common Stock and Halozyme Therapeutics, Inc. are evenly matched on the factors we track — the better pick depends on what you're optimizing for.
Size & Scale
| CRDF | HALO | |
|---|---|---|
| Market Cap | $74.71 million | $10.17 billion |
| Revenue (TTM) | — | $1.51 billion |
| Net Income (TTM) | — | $348.84 million |
HALO leads on 1 of 1 size & scale factors.
Valuation
| CRDF | HALO | |
|---|---|---|
| P/E Ratio | — | 29.99 |
| Price / Book | — | 46.31 |
| Price / Sales | — | 6.74 |
CRDF and HALO split the valuation factors evenly.
Profitability
| CRDF | HALO | |
|---|---|---|
| Net Margin | — | 23.13% |
| Return on Equity | — | 158.83% |
CRDF and HALO split the profitability factors evenly.
Risk & Sentiment
| CRDF | HALO | |
|---|---|---|
| Short Interest | 1.17% | 9.37% |
CRDF leads on 1 of 1 risk & sentiment factors.
Dig deeper: CRDF overview, CRDF financials, HALO overview, HALO financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.